OTLC OTC
Oncotelic Therapeutics, Inc.
1W: -17.0%
1M: -40.7%
3M: -49.9%
YTD: -73.0%
1Y: -69.5%
3Y: -30.0%
5Y: -83.8%
$0.02
-0.00 (-1.41%)
Weekly Expected Move ±11.9%
$0
$0
$0
$0
$0
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Supply Chain
Income Trends
Revenue
$0
-100.0% ▼
Gross Profit
$0
-100.0% ▼
Operating Income
-$3.6B
-53690.7% ▼
Net Income
-$4.5B
-57142.6% ▼
EPS (Diluted)
$-0.01
+44.0% ▲
EBITDA
-$4M
+50.5% ▲
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
| Revenue | $2M | $0 | $0 | $70K | $0 |
| YoY Growth | +0.0% | -100.0% | +0.0% | +0.0% | -100.0% |
| Cost of Revenue | $0 | $62K | $13K | $0 | $0 |
| Gross Profit | $2M | -$62K | -$13K | $70K | $0 |
| Gross Margin | 100.0% | — | — | 100.0% | — |
| R&D Expenses | $4M | $4M | $757K | $61K | $0 |
| SG&A Expenses | $5M | $5M | $5M | $574K | $376K |
| Operating Expenses | $9M | $9M | $6M | $7M | $376K |
| Operating Income | -$8M | -$9M | -$10M | -$7M | -$3.6B |
| Operating Margin | -435.7% | — | — | -9497.2% | — |
| Interest Expense | $2M | $2M | $3M | $1M | $858K |
| Income Before Tax | -$10M | -$11M | $5M | -$8M | -$4.5B |
| Tax Expense | $0 | $0 | $0 | $0 | $0 |
| Net Income | -$12M | -$11M | $18M | -$8M | -$4.5B |
| Net Margin | -660.6% | — | — | -11290.1% | — |
| EPS (Diluted) | $-0.13 | $-0.04 | $0.04 | $-0.02 | $-0.01 |
| EBITDA | -$8M | -$9M | -$6M | -$7M | -$4M |
| Shares Outstanding | 88M | 303M | 457M | 396M | 404M |